Prof-merlin-keyfact1

reduced risk of CV death
or kidney disease progression*1,2

Prof-merlin-keyfact2

reduced risk of CV death
or hospitalisation for heart failure†3,4

Prof-merlin-keyfact3

reduced risk of CV death‡5

How do the EMPA-KIDNEY results add up to the existing strong scientific evidence of empagliflozin?

RELATED CONTENT